TAG72-Targeted CAR T Cells for Ovarian Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR T cell therapies for solid cancers face challenges such as off-tumor on-target toxicity due to the lack of truly restricted tumor antigens and achieving durable responses limited by T cell persistence and tumor trafficking.
Innovation Solution
Development of TAG72-targeted CAR T cells engineered with a specific chimeric antigen receptor (CAR) design, comprising an scFv targeting TAG72, a spacer, a transmembrane domain, a 41-BB co-stimulatory domain, and a CD3 ζ signaling domain, to selectively target and kill TAG72-positive cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR T cells target over-expressed proteins in solid tumors, then tumor killing activity is achieved, but off-tumor on-target toxicity occurs due to lack of truly restricted tumor antigens
Solution Approach 1:
The patent applies local quality by targeting TAG72, a glycoprotein specifically over-expressed on the surface of ovarian cancer cells and other solid tumors, while being absent or low on normal tissues. This creates a localized attack on tumor cells with minimal impact on normal tissues, resolving the contradiction between achieving tumor killing activity and avoiding off-tumor toxicity.
Solution Approach 2:
The patent utilizes the abnormal expression level parameter of TAG72 on tumor cells versus normal cells. By designing CARs that specifically recognize and bind to TAG72 at its over-expressed state on tumor surfaces, the system achieves selective tumor targeting. The parameter change in TAG72 expression levels between tumor and normal tissues enables the CAR T cells to distinguish and attack only the tumor cells.
2Ease of manufacture
If CAR T cells are designed with standard components, then manufacturing is simplified, but T cell persistence and tumor trafficking are limited
Solution Approach 1:
The patent employs composite materials by integrating multiple functional domains into a single CAR structure: the scFv domain for antigen recognition, the spacer domain for proper spacing, the transmembrane domain for membrane anchoring, and the intracellular signaling domain for T cell activation. This composite design maintains manufacturability while enhancing T cell persistence and tumor trafficking through optimized domain interactions.
Solution Approach 2:
The patent introduces dynamics by incorporating a movable or adjustable spacer domain and optimizing the intracellular signaling domain to dynamically respond to antigen engagement. This dynamic design allows the CAR to adapt its conformation and signaling strength based on the binding conditions, thereby enhancing T cell persistence without complicating the manufacturing process.
3Reliability
If CAR T cells target TAG72 on ovarian cancer cells, then antigen-specific cytotoxicity is achieved, but T cell trafficking to the tumor site is limited
Solution Approach 1:
The patent uses an intermediary approach by incorporating a spacer domain that acts as a molecular bridge between the extracellular scFv domain and the intracellular signaling domain. This spacer intermediary optimizes the mechanical coupling and signal transmission, thereby enhancing T cell activation and trafficking speed while maintaining antigen-specific cytotoxicity against TAG72-positive ovarian cancer cells.
Solution Approach 2:
The patent applies parameter changes by optimizing the length and composition of the spacer domain and the intracellular signaling domain to enhance T cell activation kinetics. By adjusting these parameters, the system achieves faster T cell response and trafficking to the tumor site while maintaining specific cytotoxicity against TAG72-expressing cells.
Data Source
AI summary
Chimeric antigen receptors targeted to TAG72 and the use thereof to treat ovarian cancer and other cancers are described.